Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07303777 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
A Phase 2 study, sponsored by Atom Therapeutics Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07303777: Recruiting Phase 2 study, sponsored by Atom Therapeutics Co..
NCT07303777 is a Phase 2 study that is actively recruiting participants, run by Atom Therapeutics Co.. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07303777, a Phase 2 study, is actively recruiting participants, sponsored by Atom Therapeutics Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
Interventions
- DRUG Placebo
- DRUG ABP-745 Dose A
- DRUG ABP-745 Dose B
- DRUG ABP-745 Dose C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT07303777 shows while recruiting
NCT07303777 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07303777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07303777 about?
NCT07303777 is a clinical study titled "Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis". This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with AS...
What is the current status of trial NCT07303777?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-04-23. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07303777?
The interventions under investigation include: Placebo (DRUG), ABP-745 Dose A (DRUG), ABP-745 Dose B (DRUG), ABP-745 Dose C (DRUG).
Who is sponsoring clinical trial NCT07303777?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07303777's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI